section name header

Indications

BEERS REMS, High Alert


Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Availability

(Generic available)

Route/Dosage

Reduction in Risk of Stroke/Systemic Embolism in Nonvalvular Atrial Fibrillation

Renal Impairment

Treatment of and Reduction in Risk of Recurrence of Deep Vein Thrombosis or Pulmonary Embolism

Renal Impairment

Renal Impairment

Prevention of Deep Vein Thrombosis and Pulmonary Embolism Following Hip Replacement Surgery

Renal Impairment

US Brand Names

Pradaxa

Action

  • Acts as a direct inhibitor of thrombin.
Therapeutic effects:
  • Reduced risk of thrombotic sequelae (stroke and systemic embolism) in nonvalvular AF.
  • Reduced risk of recurrent PE and DVT.
  • Resolution of DVT and PE.

Classifications

Therapeutic Classification: anticoagulants

Pharmacologic Classification: thrombin inhibitors

Pharmacokinetics

Absorption: 3–7% absorbed following oral administration. Bioavailability of oral pellets higher than that of capsules in adults.

Distribution: Unknown.

Metabolism/Excretion: Of the amount absorbed, mostly excreted by kidneys (80%); 86% of ingested dose is eliminated in feces due to poor bioavailability.

Half-Life: 12–17 hr.

Time/Action Profile

(effects on coagulation)

ROUTEONSETPEAKDURATION
POwithin hrsunknown2 days

Following discontinuation, 3–5 days in renal impairment.

Patient/Family Teaching

Pronunciation

da-bi-GAT-ran

Code

NDC Code